Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866415 | 0.88 | GAA (0.60) | GAAEPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL2603252 | 0.85 | GAA (0.64) | GAAALDH1A1HTTMAPK1TDP1 | |
| SCHEMBL13826473 | 0.84 | CYP3A4 (0.57) | GAAEPHX2EPHX1ALDH1A1POLB | |
| SCHEMBL12404035 | 0.84 | GAA (0.57) | GAAEPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL12750210 | 0.84 | GAA (0.63) | GAAEPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL23573427 | 0.84 | EPHX2 (0.65) | GAAEPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL13073616 | 0.83 | ACHE (0.67) | GAAALDH1A1HTTMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL6276058 | 0.83 | EPHX1 (0.66) | EPHX2EPHX1ALDH1A1POLB | |
| SCHEMBL21183264 | 0.81 | GAA (0.62) | GAAEPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL29995238 | 0.81 | GAA (0.62) | GAAEPHX2EPHX1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | GAA 1642/4885EPHX2 1213/4885EPHX1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.